Tevogen Bio Holdings receives Nasdaq notice for minimum bid price deficiency
NegativeFinancial Markets

Tevogen Bio Holdings has received a notice from Nasdaq regarding a deficiency in its minimum bid price. This situation is significant as it indicates potential challenges for the company in maintaining its listing on the exchange, which could impact investor confidence and market perception. Companies that fail to meet Nasdaq's requirements may face delisting, making it crucial for Tevogen to address this issue promptly.
— Curated by the World Pulse Now AI Editorial System